4 Likely Biotech Takeover Targets To Buy

After biotech stock Relypsa was bought out last week for a 60% premium, the odds of M&A heating up in this sector increased dramatically. Bret Jensen shares four more likely takeover targets that should be on your watchlist.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.